AQR Capital Management
NMRA icon

AQR Capital Management’s Neumora Therapeutics NMRA Stock Holding History

AQR Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109K Sell
55,995
-38,175
-41% -$98.9K ﹤0.01% 3677
2025
Q4 		$169K Sell
94,170
-113,487
-55% -$249K ﹤0.01% 3392
2025
Q3 		$378K Sell
207,657
-568,415
-73% -$919K ﹤0.01% 2955
2025
Q2 		$569K Buy
776,072
+313,469
+68% +$237K ﹤0.01% 2544
2025
Q1 		$463K Buy
+462,603
New +$792K ﹤0.01% 2471

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

AQR Capital Management's NMRA Position: Q1 2026 in Review

AQR Capital Management reduced its Neumora Therapeutics (NMRA) stake by 41% in Q1 2026, selling an estimated $98.9K and leaving 55,995 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #3677.

AQR Capital Management first reported a position in NMRA in Q1 2025 and has held it in 5 quarters since. The position peaked at $569K in Q2 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • AQR Capital Management held 55,995 shares of Neumora Therapeutics worth $109K as of Q1 2026.
  • AQR Capital Management sold 38,175 Neumora Therapeutics shares in Q1 2026, an estimated $98.9K.
  • Neumora Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3677 holding.
  • AQR Capital Management first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • AQR Capital Management's Neumora Therapeutics position peaked at $569K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.